Pleissental-Clinic Werdau/Saxony, Germany
Title: Advantages and disadvantages of the two-stage hyperthermic intraperitoneal chemotherapy after cytoreductive surgery of patients with peritoneal carcinomatosis
Elke Wagler works in Pleissental-Clinic Werdau/Saxony, Germany.
Introduction: In case of primary peritoneal carcinomatosis of unexplained origin deferred hyperthermic intraperitoneal chemotherapy (HIPEC) is given in our oncological focused clinic. With primary confi rmed histology one-stage HIPEC will be carried out following resection. Several studies have discussed the ideal time of HIPEC in relation to intraoperatively complications. Objectives: Analysis of the results of the two-stage proceeding in terms of morbidity and mortality, Hospitalization. Methods: Peritoneal carcinomatosis patients with resection of diff erent locations were used in this for our observations. According to the histological fi ndings, the patients were treated with one- or two-stage HIPEC. Th e analysis occurred retrospectively in terms of morbidity and mortality. Results: Th e morbidity in our series was very low. One patient died due to cardiac complications. Prolonged intensive care was needed in patients with two-stage HIPEC. However, the total average length of stay in hospital was not signifi cantly higher. Th e apportionment of the individual complications will be discussed at the congress. Conclusion: Comparing the published data with the one-stage approach, a signifi cant diff erence of the total hospitalization time as well as time needed in intensive care has been shown. Th e documented morbidity and mortality is comparable to the documented results of other studies. In terms of long-term survival rates, no diff erence can be detected in our relatively small group of patients compared to the published data on one-stage procedures.